Dyax Corp. Hits New 52-Week High at $9.47 (DYAX)
Shares of Dyax Corp. (NASDAQ:DYAX) hit a new 52-week high during trading hours on Tuesday, American Banking & Market News reports. The company traded as high as $9.47 and last traded at $9.42, with a volume of 1,473,173 shares trading hands. The stock had previously closed at $8.91.
Several analysts have recently commented on the stock. Analysts at Wedbush initiated coverage on shares of Dyax Corp. in a research note to investors on Monday. They set an “outperform” rating and a $11.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Dyax Corp. from $7.00 to $8.00 in a research note to investors on Wednesday, October 23rd. They now have an “outperform” rating on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Dyax Corp. from $7.00 to $7.50 in a research note to investors on Wednesday, October 23rd. They now have an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $8.00.
Dyax Corp. has a 52 week low of $2.26 and a 52 week high of $9.29. The stock’s 50-day moving average is $7.89 and its 200-day moving average is $6.16. The company’s market cap is $1.158 billion.
Dyax Corp. (NASDAQ:DYAX) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported ($0.06) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.05) by $0.01. The company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $14.80 million. On average, analysts predict that Dyax Corp. will post $-0.28 earnings per share for the current fiscal year.
Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.